Abstract

Clopidogrel treatment response is linked to CYP2C19 activity, which is measured by the active H4 metabolite. The researchers wanted to create a physiologically based pharmacokinetic (PBPK) model of clopidogrel and its metabolites for European ancestry populations, predict pharmacokinetics in the Japanese population using the CYP2C19 phenotype, and look into the impact of clinical and demographic parameters. Using plasma data from previous research, a PBPK model was created and proven to describe the two metabolic routes of clopidogrel (H4 metabolite, acyl glucuronide metabolite) for a population of European ancestry